TrueMark Investments LLC Takes $2.72 Million Position in GSK PLC Sponsored ADR (NYSE:GSK)

TrueMark Investments LLC bought a new stake in shares of GSK PLC Sponsored ADR (NYSE:GSK - Free Report) in the first quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission (SEC). The firm bought 70,262 shares of the pharmaceutical company's stock, valued at approximately $2,722,000.

Other large investors have also recently made changes to their positions in the company. Parkside Financial Bank & Trust increased its position in GSK by 470.1% during the 4th quarter. Parkside Financial Bank & Trust now owns 992 shares of the pharmaceutical company's stock valued at $34,000 after buying an additional 818 shares in the last quarter. Lee Danner & Bass Inc. bought a new stake in GSK in the fourth quarter worth $39,000. Bank Julius Baer & Co. Ltd Zurich bought a new position in shares of GSK during the fourth quarter valued at $40,000. Atala Financial Inc bought a new position in shares of GSK during the fourth quarter valued at $45,000. Finally, Whipplewood Advisors LLC purchased a new position in shares of GSK in the 4th quarter worth about $46,000. 15.74% of the stock is currently owned by hedge funds and other institutional investors.

Wall Street Analysts Forecast Growth

GSK has been the topic of several recent analyst reports. Hsbc Global Res raised shares of GSK to a "strong sell" rating in a research report on Monday, April 28th. Wall Street Zen lowered shares of GSK from a "buy" rating to a "hold" rating in a report on Friday, May 30th. Berenberg Bank reissued a "hold" rating on shares of GSK in a report on Tuesday, June 3rd. Finally, BNP Paribas initiated coverage on GSK in a research note on Tuesday, April 15th. They issued a "neutral" rating and a $35.25 price target for the company. One research analyst has rated the stock with a sell rating, nine have given a hold rating and two have given a strong buy rating to the company. Based on data from MarketBeat.com, GSK has a consensus rating of "Hold" and an average target price of $37.38.

GSK Stock Performance

GSK stock traded up $0.40 during mid-day trading on Tuesday, reaching $38.66. 4,820,942 shares of the stock traded hands, compared to its average volume of 4,940,541. GSK PLC Sponsored ADR has a 12-month low of $31.72 and a 12-month high of $44.67. The business's 50-day moving average is $38.69 and its 200-day moving average is $36.88. The company has a debt-to-equity ratio of 1.21, a current ratio of 0.87 and a quick ratio of 0.58. The stock has a market capitalization of $79.14 billion, a PE ratio of 19.93, a price-to-earnings-growth ratio of 1.34 and a beta of 0.52.

GSK (NYSE:GSK - Get Free Report) last released its quarterly earnings results on Wednesday, April 30th. The pharmaceutical company reported $1.13 EPS for the quarter, beating the consensus estimate of $1.08 by $0.05. The firm had revenue of $10.06 billion during the quarter, compared to analyst estimates of $7.52 billion. GSK had a net margin of 9.89% and a return on equity of 48.82%. The business's revenue for the quarter was up 2.1% compared to the same quarter last year. During the same quarter in the prior year, the firm earned $0.43 EPS. As a group, sell-side analysts predict that GSK PLC Sponsored ADR will post 4.14 EPS for the current fiscal year.

GSK Increases Dividend

The firm also recently declared a quarterly dividend, which will be paid on Thursday, July 10th. Shareholders of record on Friday, May 16th will be given a $0.4216 dividend. The ex-dividend date is Friday, May 16th. This is an increase from GSK's previous quarterly dividend of $0.39. This represents a $1.69 annualized dividend and a yield of 4.36%. GSK's dividend payout ratio (DPR) is presently 87.11%.

GSK Profile

GSK plc, together with its subsidiaries, engages in the research, development, and manufacture of vaccines, and specialty and general medicines to prevent and treat disease in the United Kingdom, the United States, and internationally. It operates through two segments, Commercial Operations and Total R&D.